SanBio Co (TSE:4592) OCF Margin %: 0.00% (As of Jan. 2026)


TSE:4592 SanBio Co Ltd TSE:4592
22 GF Score
Price 円997.00
! 1 Warning Sign
View Full Analysis

What is SanBio Co OCF Margin %?

SanBio Co TSE:4592 +4.95% 22 OCF Margin % is 0.00% as of Jan. 2026. GuruFocus rates TSE:4592 with a GF Score™ of 22/100. The stock has 1 warning sign investors should review. Among 948 Biotechnology companies, SanBio Co ranks worse than 105485.13% on this metric.

OCF Margin % is calculated as Cash Flow from Operations divided by its Revenue. SanBio Co's Cash Flow from Operations for the three months ended in Jan. 2026 was 円0.00 Mil. SanBio Co's Revenue for the three months ended in Jan. 2026 was 円0.00 Mil. Therefore, SanBio Co's OCF Margin % for the quarter that ended in Jan. 2026 was 0.00%.

As of today, SanBio Co's current OCF Yield % is -4.49%.

The historical rank and industry rank for SanBio Co's OCF Margin % or its related term are showing as below:


During the past 13 years, the highest OCF Margin % of SanBio Co was -189.16%. The lowest was -1278.39%. And the median was -461.92%.

TSE:4592's OCF Margin % is not ranked *
in the Biotechnology industry.
Industry Median: -64.115
* Ranked among companies with meaningful OCF Margin % only.

SanBio Co OCF Margin % Related Terms

SanBio Co OCF Margin % Historical Data

* Premium members only.

The historical data trend for SanBio Co's OCF Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

SanBio Co OCF Margin % Chart

SanBio Co Annual Data
Trend Jan17 Jan18 Jan19 Jan20 Jan21 Jan22 Jan23 Jan24 Jan25 Jan26
OCF Margin %
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

SanBio Co Quarterly Data
Jul21 Oct21 Jan22 Apr22 Jul22 Oct22 Jan23 Apr23 Jul23 Oct23 Jan24 Apr24 Jul24 Oct24 Jan25 Apr25 Jul25 Oct25 Jan26 Apr26
OCF Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
TSE:4592
22GF Score
SanBio Co Ltd TSE:4592
OCF Margin % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

SanBio Co OCF Margin % Calculation

OCF Margin % is the ratio of Cash Flow from Operations divided by net sales or Revenue, usually presented in percent.

SanBio Co's OCF Margin for the fiscal year that ended in Jan. 2026 is calculated as

OCF Margin=Cash Flow from Operations (A: Jan. 2026 )/Revenue (A: Jan. 2026 )
=-3760.89/0
= %

SanBio Co's OCF Margin for the quarter that ended in Jan. 2026 is calculated as

OCF Margin=Cash Flow from Operations (Q: Jan. 2026 )/Revenue (Q: Jan. 2026 )
=0/0
= %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about OCF Margin % →
What does a OCF Margin % of 0.00% mean?
SanBio Co (TSE:4592) has a OCF Margin % of 0.00% as of Jan. 2026. OCF Margin is the ratio of Cash Flow from Operations to Total Revenue. View historical data on SanBio Co and its competitors. According to the industry distribution chart, SanBio Co ranks #999999 out of 948 companies in the Biotechnology industry.
Is SanBio Co's OCF Margin % too high?
SanBio Co's current OCF Margin % is 0.00%. Based on the distribution chart, SanBio Co ranks #999999 out of 948 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, SanBio Co has a GF Score™ of 22/100, reflecting its overall financial health beyond just this single metric.
How does SanBio Co's OCF Margin % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, SanBio Co ranks #999999 out of 948 companies for OCF Margin %. This places SanBio Co in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good OCF Margin % for a Biotechnology company?
A good OCF Margin % depends on the Biotechnology industry context. However, OCF Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high OCF Margin % mean?
A high OCF Margin % can signal that a stock is expensive relative to its fundamentals. OCF Margin is the ratio of Cash Flow from Operations to Total Revenue. View historical data on SanBio Co and its competitors. SanBio Co's current OCF Margin % is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is SanBio Co stock overvalued right now?
SanBio Co (TSE:4592) has a current OCF Margin % of 0.00%. The current OCF Margin % is 0.00%. SanBio Co's overall GF Score™ is 22/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is OCF Margin % calculated?
OCF Margin % is calculated from a company's financial statements. For SanBio Co (TSE:4592), the current OCF Margin % is 0.00% as of Jan. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

SanBio Co Business Description

Address 8-1 Street Luke Tower 32nd Floor, Akashi-cho, Chuo-ku, Tokyo, JPN, 104-0044
SanBio Co Ltd is engaged in the research and development of regenerative cells drugs. The company has three types of drugs under development, including nerve regeneration cell SB623, used for the treatment of chronic cerebral infarction, traumatic brain injury, age-related macular degeneration, retinitis pigmentosa, Parkinson's disease, spinal cord injury and Alzheimer's disease; enhanced type-mesenchymal stem cells SB618, used to treat peripheral neuropathy, as well as muscle stem cells SB308, used in the treatment of muscular dystrophy.
22GF Score

Get the complete analysis for TSE:4592

OCF Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

円997.00
Price